All In Biotech

Drug Trial Radar · NCT07642050

A Study to Determine if BHV-1400 is Effective and Safe in Adults With IgA Nephropathy

A Multi-Center, Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of BHV-1400 in the Treatment of IgA Nephropathy

Last checked: Nov 20, 2026Latest source record: Jun 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingPhase 3. Randomized with 420 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

420

Planned (sponsor's estimate)

Start

Jun 2026

Primary completion

Sep 2028

Study completion Oct 2029

Sponsor

Lead sponsor
Biohaven Therapeutics Ltd.Industry
Sponsor type
Industry
First posted
Jun 11, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to determine if BHV-1400 is effective and safe in the treatment of IgA Nephropathy. Participants will be randomized in a 2:1 ratio to receive either BHV-1400 or placebo.

Conditions

  • IgA Nephropathy

Interventions

  • BHV-1400Drug

    500 mg delivered subcutaneously via autoinjector

  • PlaceboDrug

    Matching placebo delivered subcutaneously via autoinjector

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from baseline in natural log-transformed Urine Protein to Creatinine Ratio (UPCR) at Week 52Time frame: Baseline to Week 52

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.